Serebral Amiloid Anjiyopati Ve Sol Atriyal Apendiks Kapama

Greenberg SM, et al. Cerebral amyloid angiopathy: a common cause of lobar intracerebral hemorrhage. J Neurol Sci. 2020;418:117147.

Charidimou A, et al. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis. Stroke. 2017;48(4):1030–1036.

Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011;70(6):871–880.

Knudsen KA, et al. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56(4):537–539.

Cannistraro RJ, Greenberg SM. The clinical dilemma of anticoagulation in cerebral amyloid angiopathy. Curr Cardiol Rep. 2018;20(11):104.

Li L, et al. Antithrombotic therapy after intracerebral hemorrhage. Stroke. 2022;53(3):942–951.

Holmes DR, et al. Percutaneous closure of the left atrial appendage. N Engl J Med. 2009;360(7):661–669.

Reddy VY, et al. Long-term results of LAA closure: the PROTECT-AF study. Circulation. 2017;135(5):366–378.

Love S, et al. Epidemiology and pathophysiology of cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2014;40(3):258–269.

Greenberg SM, et al. Diagnosis of CAA-related hemorrhage. Stroke. 2009;40(4):1305–1311.

Attems J, et al. Amyloid angiopathy in Alzheimer’s disease and its clinical implications. Acta Neuropathol. 2011;122(6):767–782.

Revesz T, et al. Genetic risk factors in cerebral amyloid angiopathy. Brain Pathol. 2009;19(2):176–183.

Charidimou A, et al. MRI markers of CAA: an update. J Stroke. 2018;20(3):273–281.

Wilson D, et al. Antithrombotic therapy and risk of intracerebral hemorrhage recurrence. Stroke. 2022;53(4):1367–1375.

Wilson D, et al. DOACs versus warfarin in CAA-related ICH. Neurology. 2021;96(20):e2521–e2530.

Biffi A, et al. Oral anticoagulation and ICH recurrence in CAA. Stroke. 2010;41(12):2868–2873.

Raposo N, et al. Recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2019;92(9):e891–e900.

Charidimou A, et al. Cortical superficial siderosis and CAA prognosis. Neurology. 2015;84(11):1152–1159.

Banerjee G, et al. Risk stratification in CAA: imaging markers and clinical correlates. Brain. 2017;140(6):1829–1839.

Hylek EM, et al. Atrial fibrillation and aging. Circulation. 2013;128(5):e36–e38.

Merella P, et al. When atrial fibrillation meets cerebral amyloid angiopathy. J Clin Med. 2023;12(5):1402.

Biffi A, et al. Warfarin use and risk of ICH in elderly patients. Neurology. 2009;72(11):998–1004.

Charidimou A, et al. Antithrombotic treatment and cerebral microbleeds. Stroke. 2018;49(7):1737–1743.

Kozberg MG, et al. A practical approach to management of CAA. Neurology. 2020;95(19):890–902.

Reddy VY, et al. Watchman device for stroke prevention: 5-year outcomes. J Am Coll Cardiol. 2017;70(24):2964–2975.

Osmancik P, et al. Amulet vs. Watchman: randomized comparison. Circulation. 2020;142(14):1325–1335.

Dukkipati SR, et al. LAA closure in high bleeding risk patients. JACC Cardiovasc Interv. 2021;14(10):1189–1199.

Schrag M, et al. Left atrial appendage closure in CAA patients: the LAA-CAA cohort. Transl Stroke Res. 2021;12(6):951–960.

Blanc C, et al. LAA closure in AF and CAA coexistence. Stroke. 2021;52(11):3538–3547.

Merella P, et al. Management of AF in CAA. World J Cardiol. 2024;16(5):235–244.

Fusco L, et al. Real-world outcomes of LAA occlusion in CAA. World J Cardiol. 2024;16(9):560–572.

Alzand BSN, et al. LAA closure and recurrent ICH. J Stroke Cerebrovasc Dis. 2020;29(10):105079.

Yaghi S, et al. LAA occlusion as a strategy for stroke prevention in ICH patients. Stroke. 2022;53(1):223–230.

Banerjee G, et al. Imaging-guided management of CAA. Curr Opin Neurol. 2021;34(1):70–78.

Caliskan E, et al. Antithrombotic regimen after LAA occlusion. Heart Rhythm. 2020;17(3):376–382.

Ketterer MW, et al. Device-related thrombosis after LAA closure. Heart. 2023;109(1):44–50.